FOLD
Amicus Therapeutics, Inc. · Healthcare
14.46
0.07%(+0.01)
Market OpenLast Updated: — ET
52W L: $5.5152W H: $14.46
$14.46
CHG+0.09 (+0.62%)
H$14.49
L$14.33
VOL57M
FOLD (1h)
Amicus Therapeutics, Inc. · Healthcare
SG Americas Securities LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 53.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 106,358 shares of the biopharmaceutical company's stock after buying an additional 36,938 shares during the
Capricorn Fund Managers Ltd bought a new stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 210,674 shares of the biopharmaceutical company's stock, valued at approximately $3,000,000. Capricorn Fund Managers Ltd
NEW YORK--(BUSINESS WIRE)--LSTA, the trade association for the U.S. corporate lending market, today was joined by SIFMA, the MFA, the Investment Company Institute and the Creditor Rights Coalition, in submitting an amicus brief in support of the defendant lenders in a misguided antitrust case filed by Optimum Communications, Inc. The complaint, one of the first of its kind, is an attempt to apply traditional antitrust principles to “Cooperation Agreements”, which have grown increasingly common.
Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 16.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,025,000 shares of the biopharmaceutical company's stock after selling 2,975,000 shares during the period.
Microsoft filed on Tuesday a proposed brief in support of Anthropic's lawsuit asking the court to temporarily block the U.S. Department of Defense's designation of the AI startup as a supply-chain risk.
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
Campbell Bradley L
director, officer: President and CEO
22,500 SH @ $14.35
2026-03-02
Campbell Bradley L
director, officer: President and CEO
75,000 SH @ $6.10
2026-01-20
Campbell Bradley L
director, officer: President and CEO
75,000 SH @ $14.31
2026-01-20
Campbell Bradley L
director, officer: President and CEO
75,000 SH @ $6.10
2026-01-20
Rosenberg Ellen
officer: Chief Legal Officer
13,426 SH @ $14.27
2026-01-02
Rosenberg Ellen
officer: Chief Legal Officer
29,683 SH @ $14.27
2026-01-03
Castelli Jeff
officer: Chief Development Officer
6,905 SH @ $14.27
2026-01-02
Castelli Jeff
officer: Chief Development Officer
23,102 SH @ $14.27
2026-01-03